Sirolimus by OrphAI Therapeutics for Bronchiolitis Obliterans: Likelihood of Approval

Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.

Cantourage Group SE records strong growth in revenue and EBITDA in the break-even range in 2023. Strong growth since the partial legalisation of cannabis came into force. – Biotech Investments

EQS-News: Cantourage Group SE / Key word(s): Annual Results/Quarter Results Cantourage Group SE records strong growth in revenue and EBITDA in the break-even range in

May 16, 2024

Ori Biotech, Cytiva separately unveil tech to accelerate cell therapy production

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

May 30, 2024

German biotech’s efforts to revive obesity target for solid tumors yield positive PhIIa results

CatalYm’s solid tumor candidate, which targets a protein previously explored in obesity, has boosted responses in combination with an immune checkpoint inhibitor in an early-stage

December 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.